

Barbara Meissner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12111379/publications.pdf>

Version: 2024-02-01

26
papers

5,516
citations

279798

23
h-index

552781

26
g-index

28
all docs

28
docs citations

28
times ranked

7879
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. <i>Blood</i> , 2021, 137, 2196-2208.	1.4	18
2	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. <i>Nature Medicine</i> , 2020, 26, 577-588.	30.7	46
3	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. <i>Blood</i> , 2020, 136, 572-584.	1.4	44
4	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2019, 134, 802-813.	1.4	96
5	The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. <i>Blood</i> , 2019, 134, 1528-1532.	1.4	82
6	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. <i>Cancer Discovery</i> , 2019, 9, 546-563.	9.4	213
7	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 190-201.	1.6	257
8	Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 203-214.	2.8	58
9	High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. <i>Blood Advances</i> , 2018, 2, 2755-2765.	5.2	74
10	Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. <i>Nature Communications</i> , 2018, 9, 4001.	12.8	102
11	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. <i>Blood</i> , 2017, 129, 2760-2770.	1.4	112
12	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. <i>PLoS Medicine</i> , 2016, 13, e1002197.	8.4	185
13	Cell of origin of transformed follicular lymphoma. <i>Blood</i> , 2015, 126, 2118-2127.	1.4	91
14	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. <i>Journal of Clinical Oncology</i> , 2015, 33, 2848-2856.	1.6	334
15	Pharmacological and genomic profiling identifies NF- κ B-targeted treatment strategies for mantle cell lymphoma. <i>Nature Medicine</i> , 2014, 20, 87-92.	30.7	303
16	Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014, 124, 703-703.	1.4	5
17	The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. <i>Blood</i> , 2013, 121, 3161-3164.	1.4	124
18	Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. <i>Blood</i> , 2013, 122, 1256-1265.	1.4	349

#	ARTICLE	IF	CITATIONS
19	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. <i>Blood</i> , 2012, 119, 1963-1971.	1.4	313
20	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. <i>Nature</i> , 2011, 476, 298-303.	27.8	1,428
21	Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. <i>Blood</i> , 2011, 117, 2451-2459.	1.4	556
22	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. <i>Nature</i> , 2011, 471, 377-381.	27.8	551
23	Determining the Sub-Cellular Localization of Proteins within <i>Caenorhabditis elegans</i> Body Wall Muscle. <i>PLoS ONE</i> , 2011, 6, e19937.	2.5	44
24	An Integrated Strategy to Study Muscle Development and Myofilament Structure in <i>Caenorhabditis elegans</i> . <i>PLoS Genetics</i> , 2009, 5, e1000537.	3.5	89
25	PEPT1-mediated uptake of dipeptides enhances the intestinal absorption of amino acids via transport system b ₀ +. <i>Journal of Cellular Physiology</i> , 2001, 186, 251-259.	4.1	38
26	PEPT1-mediated uptake of dipeptides enhances the intestinal absorption of amino acids via transport system b ₀ . <i>Journal of Cellular Physiology</i> , 2001, 186, 251-259.	4.1	1